Also, the MLL(11q23.3) mutation in charge of dismal prognosis and common therapy refractoriness in ALL patients [53] correlated with the resistance to all studied antitumor drugs: Daunorubicin (r = 0.33), cytarabine (r = 0.32), doxorubicin (r = 0.29), and vincristine (r = 0.22) (Table S6). This evidence concerns the gene KMT2A and acute lymphoblastic leukemia.